ArticleAdvances in therapy2026
Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionColorectal cancer (CRC) screening remains below national targets among US women. Primary care providers (PCPs) play an important role in promoting CRC screening adherence. Many US women see an obstetrician/gynecologist (OB/GYN) as their PCP. We evaluated adherence among US women to multi-target stool DNA (mt-sDNA) testing and follow-up colonoscopy ordered by OB/GYNs.
methodsWe linked Exact Sciences Laboratories (ESL) orders with a national multi-payer claims database (2016-2022). Eligible participants were average-risk women aged 45-75 years with continuous health plan enrollment (- 180 to 0 days baseline; 0-365 days to assess mt-sDNA adherence; and, after a positive mt-sDNA result, 0-365 days to assess colonoscopy). Primary outcomes were mt-sDNA completion within 365 days of kit shipment and colonoscopy completion within 365 days of a positive mt-sDNA test. Logistic regression evaluated factors associated with mt-sDNA adherence.
resultsOf 160,068 women with OB/GYN-ordered mt-sDNA, 71.4% (n = 114,360/160,068) completed testing within 365 days. Test positivity was 8.6% (n = 9773/114,360). Among those with positive results, 71.3% (n = 6971/9773) completed colonoscopy within 365 days. Test adherence increased with age (45-49 years, 67.1%; 50-64 years, 71.8%; 65-75 years, 76.7%), was higher in non-metropolitan areas, and rose with higher ZIP code median household income. Test adherence was higher among individuals with traditional Medicare (85.2%) and Medicare Advantage (77.3%) than commercial insurance (71.3%) and Medicaid (61.7%).
conclusionIn routine practice, more than 70% of women completed OB/GYN-ordered mt-sDNA testing and, after a positive result, more than 70% completed colonoscopy within 1 year. OB/GYN clinicians may play a key role in improving CRC screening adherence, with opportunities to address gaps by payer, income, and race/ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.